These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Aprikian AG; Herr HW; Bajorin DF; Bosl GJ Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456 [TBL] [Abstract][Full Text] [Related]
31. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival. Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619 [TBL] [Abstract][Full Text] [Related]
32. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration. Kildahl-Andersen A; Erke MG; Sagstuen H; Bremnes RM Acta Oncol; 2005; 44(6):537-44. PubMed ID: 16165912 [TBL] [Abstract][Full Text] [Related]
33. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors]. Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998 [TBL] [Abstract][Full Text] [Related]
34. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156 [TBL] [Abstract][Full Text] [Related]
35. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110 [TBL] [Abstract][Full Text] [Related]
36. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612 [TBL] [Abstract][Full Text] [Related]
37. Current management of stage I testicular non-seminomatous germ cell tumours. Pectasides D; Pectasides E; Constantinidou A; Aravantinos G Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019 [TBL] [Abstract][Full Text] [Related]
38. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer. Heidenreich A; Paffenholz P; Nestler T; Pfister D Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568 [TBL] [Abstract][Full Text] [Related]
39. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors. Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752 [TBL] [Abstract][Full Text] [Related]
40. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]